---
schema_version: "secwatch.filing_event.v1"
accession: "0001640334-22-000444"
form_type: "8-K"
ticker: "ARTL"
cik: "0001621221"
company_name: "ARTELO BIOSCIENCES, INC."
filed_at: "2022-03-10T23:59:59+00:00"
generated_at: "2026-06-26T23:59:02.776340+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Artelo Bio CAReS trial on track; board approves 2022 goals, cuts quorum to 35%

## Summary
- CEO Gorgas eligible for 2022 bonus based on goals: clinical (40%), pre-clinical (35%), financial (25%).
- Bylaws amended to reduce shareholder quorum requirement to 35%.
- CAReS Phase 1 enrollment for ART27.13 expected to complete by end of Q1 2022.
- Phase 1 results to inform dose selection within ~6 weeks of last patient; optional fourth cohort possible.
- Company currently sees no significant COVID-19 impact on trial.

## SEC filing metadata
- accession: 0001640334-22-000444
- form_type: 8-K
- ticker: ARTL
- cik: 0001621221
- company_name: ARTELO BIOSCIENCES, INC.
- filed_at: 2022-03-10T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/0001640334-22-000444-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1621221/000164033422000444/artl_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001640334-22-000444
- JSON: https://secwatch.observer/filing/0001640334-22-000444.json
- Plain text: https://secwatch.observer/filing/0001640334-22-000444.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.